SymbioCellTech's Unattributed - II Round

SymbioCellTech raised a round of funding on June 30, 2016.

SymbioCellTech is a biotechnology start-up that has developed a patented, proprietary therapy to cure insulin-dependent Type I diabetes Mellitus (T1DM), which is commonly referred to as Type 1 or juve…

Articles about SymbioCellTech's Unattributed - II Round: